Agenix Limited (ASX:AGX) is a biopharmaceutical company based in Melbourne, Australia. Through its wholly owned subsidiaries, Agen Biomedical (headquartered in Melbourne, Australia) and Agenix Biopharmaceutical (in Shanghai, China), the Company has a strategic goal of building and developing a line of therapeutic and imaging products. 
Agenix Limited (ASX:AGX) is pleased to provide Chairman's Address to shareholders at 2011 Annual General Meeting.
Agenix Limited (ASX:AGX) today confirmed it had signed two new agreements with its strategic partners in China covering the commercialisation of new drug candidates, the sharing of resources, expertise and completion of pre-clinical toxicology tests for its new hepatitis B drug in China.
Agenix Limited (ASX:AGX) confirmed its promising new hepatitis B drug, AGX-1009, shared the same active compound as Gilead's blockbuster drug, Viread, which is widely used to treat HIV and hepatitis throughout Asia.
Asian Activities Report for September 27, 2011 includes: General Mining Corporation Limited (ASX:GMM) has signed an agreement to acquire a coal exploration licence in Mongolia; Aphrodite Gold Limited (ASX:AQQ) announced further robust gold intersections at its Aphrodite Gold Deposit; Agenix Limited (ASX:AGX) has filed a patent application for its hepatitis B drug AGX-1009; Manas Resources Limited (ASX:MSR) reported a 20% increase in its Shambesai Total Mineral Resource to 766,000 ounces of gold; Infotech Enterprises Limited (BOM:532175) announced its partnership with Software Engineering Institute.
Asian Activities Report for June 8, 2011 includes: Agenix (ASX:AGX) is on track to begin clinical trials in China for its lead Hepatitis B drug; Central Asia Resources Limited (ASX:CVR) reported gold resource increase to 124,000 ounces at Dalabai Gold Project; Tanami Gold NL (ASX:TAM) announced a further substantial increase in its gold Mineral Resources to 2.30 million ounces of gold; Corazon Mining Limited (ASX:CZN) confirmed the existence of a high-grade nickel/copper sulphide discovery at the Lynn Lake nickel sulphide project in Canada.
The August 2006 edition of our Health & Life Science Quarterly Blue Book profiles niche life sciences companies, with a focus on company strategies, key projects and significant milestones.
